Tobias E. Larsson

10.1k total citations · 2 hit papers
95 papers, 7.9k citations indexed

About

Tobias E. Larsson is a scholar working on Nephrology, Genetics and Nutrition and Dietetics. According to data from OpenAlex, Tobias E. Larsson has authored 95 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Nephrology, 33 papers in Genetics and 27 papers in Nutrition and Dietetics. Recurrent topics in Tobias E. Larsson's work include Parathyroid Disorders and Treatments (67 papers), Genetic Syndromes and Imprinting (29 papers) and Magnesium in Health and Disease (27 papers). Tobias E. Larsson is often cited by papers focused on Parathyroid Disorders and Treatments (67 papers), Genetic Syndromes and Imprinting (29 papers) and Magnesium in Health and Disease (27 papers). Tobias E. Larsson collaborates with scholars based in Sweden, United States and Netherlands. Tobias E. Larsson's co-authors include Östen Ljunggren, Lars Lind, Kenneth B. Jonsson, Anders Larsson, Hannes Olauson, Harald Jüppner, Majd A.I. Mirza, Peter Stenvinkel, Richard Marsell and Kenneth E. White and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Circulation.

In The Last Decade

Tobias E. Larsson

94 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia

2003 683 citations Kenneth B. Jonsson, Tobias E. Larsson et al. profile →
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

2003 544 citations Tobias E. Larsson, Östen Ljunggren et al. Kidney International profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tobias E. Larsson Sweden	46	6.0k	2.7k	1.9k	1.8k	1.6k	95	7.9k
William G. Goodman United States	60	9.7k 1.6×	1.7k 0.6×	1.4k 0.7×	3.1k 1.7×	3.4k 2.1×	185	13.8k
Cees Vermeer Netherlands	69	3.5k 0.6×	1.2k 0.5×	1.7k 0.9×	1.6k 0.9×	9.8k 6.1×	305	14.8k
Pascal Houillier France	42	3.0k 0.5×	358 0.1×	2.2k 1.2×	710 0.4×	892 0.6×	169	6.6k
Fredric L. Coe United States	60	3.3k 0.6×	789 0.3×	1.7k 0.9×	1.4k 0.8×	734 0.5×	236	11.1k
Toru Yamaguchi Japan	51	1.4k 0.2×	508 0.2×	3.4k 1.8×	900 0.5×	746 0.5×	236	8.1k
Khashayar Sakhaee United States	51	3.2k 0.5×	318 0.1×	1.4k 0.8×	1.0k 0.6×	585 0.4×	175	8.8k
Lars Melholt Rasmussen Denmark	47	932 0.2×	855 0.3×	2.9k 1.5×	486 0.3×	349 0.2×	288	8.2k
Saı̈d Kamel France	41	1.1k 0.2×	377 0.1×	1.5k 0.8×	749 0.4×	562 0.4×	132	4.6k
Weibo Xia China	30	941 0.2×	1.0k 0.4×	1.2k 0.6×	568 0.3×	247 0.2×	290	4.2k
John R. Asplin United States	45	2.0k 0.3×	418 0.2×	1.1k 0.6×	830 0.5×	747 0.5×	164	6.3k

Countries citing papers authored by Tobias E. Larsson

Since Specialization

Citations

This map shows the geographic impact of Tobias E. Larsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tobias E. Larsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tobias E. Larsson more than expected).

Fields of papers citing papers by Tobias E. Larsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tobias E. Larsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tobias E. Larsson. The network helps show where Tobias E. Larsson may publish in the future.

Co-authorship network of co-authors of Tobias E. Larsson

This figure shows the co-authorship network connecting the top 25 collaborators of Tobias E. Larsson. A scholar is included among the top collaborators of Tobias E. Larsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tobias E. Larsson. Tobias E. Larsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lindberg, Karolina, О. А. Овчинникова, Matthias B. Moor, et al.. (2025). Fgf23 expression increases atherosclerotic plaque burden in male ApoE deficient mice. Atherosclerosis. 403. 119158–119158.

Mazer, C. David, Johannes Boehm, Craig Brown, et al.. (2023). Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial). BMJ Open. 13(4). e068363–e068363. 2 indexed citations

García-Hernández, Alberto, et al.. (2020). Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model. Journal of Pharmacokinetics and Pharmacodynamics. 48(1). 39–53. 1 indexed citations

Zhou, Bo, Xianjing Feng, Sujit Kootala, et al.. (2019). Carbazate modified dextrans as scavengers for carbonylated proteins. Carbohydrate Polymers. 232. 115802–115802. 11 indexed citations

Fan, Yi, Weiqing Liu, Ruiye Bi, et al.. (2018). Interrelated role of Klotho and calcium-sensing receptor in parathyroid hormone synthesis and parathyroid hyperplasia. Proceedings of the National Academy of Sciences. 115(16). E3749–E3758. 41 indexed citations

Komaba, Hirotaka, Jovana Kaludjerovic, Dorothy Hu, et al.. (2017). Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney International. 92(3). 599–611. 86 indexed citations

Ide, Noriko, Hannes Olauson, Tadatoshi Sato, et al.. (2016). In vivo evidence for a limited role of proximal tubular Klotho in renal phosphate handling. Kidney International. 90(2). 348–362. 57 indexed citations

Carlsson, Axel C., Tobias E. Larsson, Johanna Helmersson‐Karlqvist, et al.. (2014). Soluble TNF Receptors and Kidney Dysfunction in the Elderly. Journal of the American Society of Nephrology. 25(6). 1313–1320. 31 indexed citations

Mazzaferro, Sandro, David Goldsmith, Tobias E. Larsson, Ziad A. Massy, & Mario Cozzolino. (2014). Vitamin D Metabolites and/or Analogs: Which D for Which Patient?. Current Vascular Pharmacology. 12(2). 339–349. 47 indexed citations

10.

Olauson, Hannes, Karolina Lindberg, Risul Amin, et al.. (2013). Parathyroid-Specific Deletion of Klotho Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion. PLoS Genetics. 9(12). e1003975–e1003975. 122 indexed citations

11.

Carlsson, Axel C., Anders Larsson, Johanna Helmersson‐Karlqvist, et al.. (2012). Urinary Kidney Injury Molecule 1 and Incidence of Heart Failure in Elderly men. European Journal of Heart Failure. 15(4). 441–446. 30 indexed citations

12.

Hagström, Emil, Erik Ingelsson, Johan Sundström, et al.. (2010). Plasma Parathyroid Hormone and Risk of Congestive Heart Failure in the Community. European Journal of Heart Failure. 12(11). 1186–1192. 87 indexed citations

13.

Krajisnik, Tijana, Hannes Olauson, Majd A.I. Mirza, et al.. (2010). Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney International. 78(10). 1024–1032. 94 indexed citations

14.

Olauson, Hannes, Vincent Brandenburg, & Tobias E. Larsson. (2010). Mutation analysis and serum FGF23 level in a patient with pulmonary alveolar microlithiasis. Endocrine. 37(2). 244–248. 12 indexed citations

15.

Olauson, Hannes, Göran Toss, Björn Wíkström, et al.. (2008). Preoperative Tumor Localization by Means of Venous Sampling for Fibroblast Growth Factor-23 in a Patient with Tumor-Induced Osteomalacia. Endocrine Practice. 14(3). 362–367. 13 indexed citations

16.

Marsell, Richard, Elin Grundberg, Tijana Krajisnik, et al.. (2008). Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. European Journal of Endocrinology. 158(1). 125–129. 59 indexed citations

17.

Krajisnik, Tijana, Peyman Björklund, Richard Marsell, et al.. (2007). Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells. Journal of Endocrinology. 195(1). 125–131. 349 indexed citations

18.

Larsson, Tobias E., Margareta Wedborg, & David R. Turner. (2006). Correction of inner-filter effect in fluorescence excitation-emission matrix spectrometry using Raman scatter. Analytica Chimica Acta. 583(2). 357–363. 142 indexed citations

19.

Larsson, Tobias E., Richard Marsell, Ernestina Schipani, et al.. (2004). Transgenic Mice Expressing Fibroblast Growth Factor 23 under the Control of the α1(I) Collagen Promoter Exhibit Growth Retardation, Osteomalacia, and Disturbed Phosphate Homeostasis. Endocrinology. 145(7). 3087–3094. 393 indexed citations

20.

Larsson, Tobias E., et al.. (2003). Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney International. 64(6). 2272–2279. 544 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact